Sponsored and organized by:
|

WHERE INNOVATIVE LIFE SCIENCE COMPANIES
MEET
INVESTORS
// Next
Edition
March 1st-2nd 2022//
Euro-Swiss Technopole
//Archamps//France
BioData
2022 |
Dear
Participants,
Remember
the Summer of 1998?
The cash dried out very rapidly before August. Biotech teams within venture
funds were disbanded. HighTech was strong, biotech pariah.
The
rebound was amazingly rapid and strong. Suddenly, thanks to a few good
news from Biotech pipelines of drugs and large acquisitions by big pharma
the sector replenished its cash reserves in a few months. Biotech analysts
found a new employer. The heroes were those who kept their investment
in the so-called debacle of the Summer.
Just to say, it is a particular time, when investors exit in
mass a sector, the time when the braves can make huge amount
of money. Today is somewhat different because the financial crisis
is not specific to a sector nor due to the respective expectations
for one sector (hightech) vs another (biotech).
Nevertheless, valuations are historically low, even if the shy will not
recognize it. The lack of cash is both the result and the cause
of the situation. Unemployed cash is idle but enormous compare to
the size of the smallcap lifescience market. When the cash will come back
to chase growth opportunities, the valuation will surge.
In other words, low valuations are always opportunities for those who
can afford to buy when nobody wants to do it, stick
as long as needed until the day comes when everybody
will want to buy.
BioData
2022 will introduce to investors the most resilient entrepreneurs. Only
the best projects survive in this tough times. This is the reason why
probably the most promising projects in the history of BioData will be
presented in March 2022.
Looking
forward to meeting you again at BioData2022!
The Organization
Committee
Hervé de Kergrohen , MD |
Liliane Daugny , MD |
Cédric Loiret-Bernal, MD |
Chairman |
|
|
|
|
|
Chairman
|